MAY2013-02-02 "Pilot Study of EGFR Inhibition with Erlotinib in Cirrhosis to Inhibit Fibrogenesis and Prevent Hepatocellular Carcinoma"

  • Are you or do you have...?
    • 18 years of age or older and fairly healthy?
    • Scheduled for surgery to remove part of your liver because of cirrhosis, fibrosis, or early cancer? Or, have you had a liver biopsy in the past 2 months to evaluate cirrhosis, fibrosis, or early cancer?
    • Willing to provide blood and tissue specimens for research?
    • No evidence of HIV infection?
  • You may be eligible for a clinical trial opening soon that will test a drug called erlotinib that may be effective in preventing liver cancer.
    • Enrolling sites in Rochester, MN; Boston, MA; Indianapolis, IN, Jacksonville, FL, New York City, NY; and Cleveland, OH.
    • The study involves 3 study visits, blood tests, a biopsy of your liver, daily phone calls, taking erlotinib for about 7 days prior to your surgery or biopsy, and questionnaires about your side effects, symptoms, and experience on the study
    • You will be on the study for 1-2 weeks.
    • You won't be paid for participant but you may receive funds to help with your expenses while on the study.
    • If you choose to participate, there may be risks associated with the biopsy and with erlotinib, such as loss of appetite, nausea, or fatigue.
    • There may or may not be a direct benefit for you. We do not know whether or not erlotinib will prevent liver cancer. However, if the results from this clinical trial are positive, we may be closer to prevention of liver cancer.
  • If you are interested, email the Cancer Prevention Network Operations Office, or call 507-284-1602